Parkin-linked Parkinson's disease: From clinical insights to pathogenic mechanisms and novel therapeutic approaches

Kobi Wasner, Anne Grünewald, Christine Klein*

*Corresponding author for this work

    Abstract

    With over 7 million patients worldwide, Parkinson's disease (PD) is becoming more prevalent as life span and industrialization increase. While the majority of cases are sporadic and present in individuals over 65, inherited mutations in Parkin can manifest in individuals as young as teenagers. The involvement of Parkin in neurodegeneration has been widely investigated and its role in mitophagy is undeniable. In the recent years, however, additional functions of the protein are beginning to come to light, which in turn may influence the way patients harboring Parkin mutations are treated. In the present article, we discuss the clinical and genetic aspects of Parkin-linked PD. For this purpose, we consulted the MDSGene database, which comprises the literature of more than 1000 patients with Parkin mutations. In addition, we provide insight into Parkin's multifaceted role in mitochondrial clearance and maintenance. Finally, we discuss treatment strategies such as brain stimulation, small molecule drugs and dopaminergic cell replacement that could be tailored to improve the clinical phenotypes in Parkin-linked PD.

    Original languageEnglish
    JournalNeuroscience Research
    ISSN0168-0102
    DOIs
    Publication statusPublished - 17.09.2020

    Research Areas and Centers

    • Research Area: Medical Genetics

    Fingerprint

    Dive into the research topics of 'Parkin-linked Parkinson's disease: From clinical insights to pathogenic mechanisms and novel therapeutic approaches'. Together they form a unique fingerprint.

    Cite this